Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNA4 | P43681 | 3/20 | 0.39 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.37 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.37 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.37 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.37 |
| ▸ | P2RY14 | Q15391 | 1/20 | 0.35 |
| ▸ | CDK9 | P50750 | 2/20 | 0.33 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.33 |
| ▸ | PRKCZ | Q05513 | 1/20 | 0.32 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.31 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.31 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.31 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.31 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15596503 | 0.76 | P2RY14 (0.42) | CHRNA4CHRNB2CHRNB4CHRNA3CHRNA7 | |
| SCHEMBL15596271 | 0.76 | P2RY14 (0.42) | CHRNA4CHRNB2CHRNB4CHRNA3CHRNA7 | |
| SCHEMBL16941423 | 0.76 | P2RY14 (0.42) | CHRNA4CHRNB2CHRNB4CHRNA3CHRNA7 | |
| SCHEMBL14704704 | 0.76 | P2RY14 (0.42) | CHRNA4CHRNB2CHRNB4CHRNA3CHRNA7 | |
| SCHEMBL15596510 | 0.73 | CHRNB2 (0.54) | CHRNA4CHRNB2CHRNB4CHRNA3CHRNA7 | |
| SCHEMBL5937544 | 0.73 | CHRNB2 (0.54) | CHRNA4CHRNB2CHRNB4CHRNA3CHRNA7 | |
| SCHEMBL5937537 | 0.73 | CHRNB2 (0.54) | CHRNA4CHRNB2CHRNB4CHRNA3CHRNA7 | |
| SCHEMBL29602035 | 0.73 | P2RY14 (0.41) | CHRNA4CHRNB2CHRNB4CHRNA3CHRNA7 | |
| SCHEMBL22805515 | 0.73 | P2RY14 (0.41) | CHRNA4CHRNB2CHRNB4CHRNA3CHRNA7 | |
| SCHEMBL5937541 | 0.73 | CHRNB2 (0.54) | CHRNA4CHRNB2CHRNB4CHRNA3CHRNA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190194194-A1 | ANTIBACTERIAL CYCLOPENTA[C]PYRROLE SUBSTITUTED 3,4-DIHYDRO-1H-[1,8]NAPHTHYRIDINONES | Janssen Sciences Ireland Unlimited Company (IE) | 2019-06-27 | — | — | US | disclosed |
| US-20190084982-A1 | ANTIBACTERIAL CYCLOPENTA[C]PYRROLE SUBSTITUTED 3,4-DIHYDRO-1H-[1,8]NAPHTHYRIDINONES | Janssen Sciences Ireland Unlimited Company (IE) | 2019-03-21 | — | — | US | disclosed |
| EP-2742045-B1 | ANTIBACTERIAL CYCLOPENTA[C]PYRROLE SUBSTITUTED 3,4-DIHYDRO-1H-[1,8]NAPHTHYRIDINONES | JANSSEN SCIENCES IRELAND UNLIMITED CO (IE) | 2019-01-23 | — | — | EP | disclosed |
| US-20180105525-A1 | ANTIBACTERIAL CYCLOPENTA[C]PYRROLE SUBSTITUTED 3,4-DIHYDRO-1H-[1,8]NAPHTHYRIDINONES | Janssen Sciences Ireland Unlimited Company (IE) | 2018-04-19 | — | — | US | disclosed |
| US-20180105525-A1 | ANTIBACTERIAL CYCLOPENTA[C]PYRROLE SUBSTITUTED 3,4-DIHYDRO-1H-[1,8]NAPHTHYRIDINONES | Janssen Sciences Ireland Unlimited Company (IE) | 2018-04-19 | — | — | US | disclosed |
| US-9884864-B2 | Antibacterial cyclopenta[C]pyrrole substituted 3,4-Dihydro-1H-[1,8]naphthyridinones | JANSSEN SCIENCES IRELAND UC (IE) | 2018-02-06 | — | — | US | disclosed |
| US-9884864-B2 | Antibacterial cyclopenta[C]pyrrole substituted 3,4-Dihydro-1H-[1,8]naphthyridinones | JANSSEN SCIENCES IRELAND UC (IE) | 2018-02-06 | — | — | US | disclosed |
| US-20170174683-A1 | ANTIBACTERIAL CYCLOPENTA[C]PYRROLE SUBSTITUTED 3,4-DIHYDRO-1H-[1,8]NAPHTHYRIDINONES | Janssen Sciences Ireland Unlimited Company (IE) | 2017-06-22 | — | — | US | disclosed |
| US-20170174683-A1 | ANTIBACTERIAL CYCLOPENTA[C]PYRROLE SUBSTITUTED 3,4-DIHYDRO-1H-[1,8]NAPHTHYRIDINONES | Janssen Sciences Ireland Unlimited Company (IE) | 2017-06-22 | — | — | US | disclosed |
| US-9617262-B2 | Antibacterial cyclopental[C]pyrrole substituted 3,4-dihydro-1H-[1,8]naphthyridinones | JANSSEN SCIENCES IRELAND UC (IE) | 2017-04-11 | — | — | US | disclosed |
| US-20160194324-A1 | ANTIBACTERIAL CYCLOPENTAL[C]PYRROLE SUBSTITUTED 3,4 DIHYDRO-1H-[1,8]NAPHTHYRIDINONES | Janssen Sciences Ireland Unlimited Company (IE) | 2016-07-07 | — | — | US | disclosed |
| US-9290493-B2 | Antibacterial cyclopenta[c]pyrrole substituted 3,4-dihydro-1H-[1,8]naphthyridinones | JANSSEN SCIENCES IRELAND UC (IE) | 2016-03-22 | — | — | US | disclosed |
| US-9290493-B2 | Antibacterial cyclopenta[c]pyrrole substituted 3,4-dihydro-1H-[1,8]naphthyridinones | JANSSEN SCIENCES IRELAND UC (IE) | 2016-03-22 | — | — | US | disclosed |
| US-20150080413-A1 | Antibacterial cyclopenta[c]pyrrole substituted 3,4-dihydro-1H-[1,8]naphthyridinones | Janssen Sciences Ireland Unlimited Company (IE) | 2015-03-19 | — | — | US | disclosed |
| US-20150080413-A1 | Antibacterial cyclopenta[c]pyrrole substituted 3,4-dihydro-1H-[1,8]naphthyridinones | Janssen Sciences Ireland Unlimited Company (IE) | 2015-03-19 | — | — | US | disclosed |
| US-8906923-B2 | Antibacterial cyclopenta[c]pyrrole substituted 3,4-dihydro-1H-[1,8]naphthyridinones | JANSSEN R&D IRELAND (IE) | 2014-12-09 | — | — | US | disclosed |
| US-8906923-B2 | Antibacterial cyclopenta[c]pyrrole substituted 3,4-dihydro-1H-[1,8]naphthyridinones | JANSSEN R&D IRELAND (IE) | 2014-12-09 | — | — | US | disclosed |
| US-20140171451-A1 | Antibacterial cyclopenta[c]pyrrole substituted 3,4-dihydro-1H-[1,8]naphthyridinones | JANSSEN R&D IRELAND (IE) | 2014-06-19 | — | — | US | disclosed |
| US-20140171451-A1 | Antibacterial cyclopenta[c]pyrrole substituted 3,4-dihydro-1H-[1,8]naphthyridinones | JANSSEN R&D IRELAND (IE) | 2014-06-19 | — | — | US | disclosed |
| WO-2013021054-A1 | ANTIBACTERIAL CYCLOPENTA[C]PYRROLE SUBSTITUTED 3,4-DIHYDRO-1H-[1,8]NAPHTHYRIDINONES | JANSSEN R&D IRELAND (IE) | 2013-02-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190084982-A1 | ANTIBACTERIAL CYCLOPENTA[C]PYRROLE SUBSTITUTED 3,4-DIHYDRO-1H-[1,8]NAPHTHYRIDINONES | ECI1, ALPI, PREP | CHRNA4 4812/4885CHRNB2 4880/4885CHRNB4 4869/4885 |
| US-20150080413-A1 | Antibacterial cyclopenta[c]pyrrole substituted 3,4-dihydro-1H-[1,8]naphthyridinones | ECI1, ALPI, PREP | CHRNA4 4812/4885CHRNB2 4880/4885CHRNB4 4869/4885 |
| US-20140171451-A1 | Antibacterial cyclopenta[c]pyrrole substituted 3,4-dihydro-1H-[1,8]naphthyridinones | ECI1, ALPI, PREP | CHRNA4 4812/4885CHRNB2 4880/4885CHRNB4 4869/4885 |
| US-20160194324-A1 | ANTIBACTERIAL CYCLOPENTAL[C]PYRROLE SUBSTITUTED 3,4 DIHYDRO-1H-[1,8]NAPHTHYRIDINONES | ECI1, ALPI, CYP51A1 | CHRNA4 4647/4885CHRNB2 4839/4885CHRNB4 4785/4885 |
| US-20170174683-A1 | ANTIBACTERIAL CYCLOPENTA[C]PYRROLE SUBSTITUTED 3,4-DIHYDRO-1H-[1,8]NAPHTHYRIDINONES | ECI1, ALPI, PREP | CHRNA4 4812/4885CHRNB2 4880/4885CHRNB4 4869/4885 |
| US-20190194194-A1 | ANTIBACTERIAL CYCLOPENTA[C]PYRROLE SUBSTITUTED 3,4-DIHYDRO-1H-[1,8]NAPHTHYRIDINONES | ECI1, ALPI, PREP | CHRNA4 4812/4885CHRNB2 4880/4885CHRNB4 4869/4885 |
| US-20180105525-A1 | ANTIBACTERIAL CYCLOPENTA[C]PYRROLE SUBSTITUTED 3,4-DIHYDRO-1H-[1,8]NAPHTHYRIDINONES | ECI1, ALPI, PREP | CHRNA4 4812/4885CHRNB2 4880/4885CHRNB4 4869/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.